Pricing Log in Create free account
Saturday 17 October 2026 Export JANX’s income statement to Excel — free account

Janux Therapeutics, Inc.

JANX Healthcare Biotechnology

Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.

16.49 0.83 −4.79%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−7.8×
Dividend yield
—
F-score
2/9
Altman Z
11.61
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.56
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 1 6 — — — 1 1 — — — —
Insider Ownership 8.11%

Capital & Financial Ratios $m

Market Cap 1,060.00
Revenue 24.00
Net Income (102.59)
Free Cash Flow (41.92)
Net Debt (970.91)
Current Ratio 16.35 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (7.79) (negative: loss-making)
P/S ratio 43.24 (above 10: high)
P/B ratio 1.12
Past 5Y EPS Growth —
This Y EPS Growth 4.60%
Next Y EPS Growth (53.18%) (below 0%: weak)
Next Y revenue growth 194.20% (at or above 10%: strong)
Next 5Y EPS Growth (22.05%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 28.2×; over the ten years it ranged from −6.6× in 2023 to 294× in 2024.
P/S against its own 10 years 6.23%
10-year low 10-year high
P/B against its own 10 years 23.74%
10-year low 10-year high
EV/Sales against its own 10 years 4.22%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 344 1,025 967 971
Receivables — — — 0
Inventory — — — —
Other — — — —
349 1,034 976 983
2023 2024 2025 Q'26
Payables 2 4 5 3
ST’ Debt — — — —
Other — — — —
13 17 25 60

Compound Annual Growth %

10y 5y 3y
Sales — — 5.11%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 167.50% 43.95%

Revenue $m

Mar Jun Sep Dec Year
’26 4 10 — — —
’25 — — 10 — 10
’24 1 9 0 0 11
’23 2 1 3 2 8
’22 2 2 2 3 9
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) 12 — — —
’25 (17) (24) (13) (29) (82)
’24 (15) (10) (2) (17) (44)
’23 (14) (15) (12) (10) (51)
’22 (12) (6) (13) (12) (43)
’21 6 (6) (6) (10) (17)
’20 (1) (2) (1) (2) (4)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) 12 — — —
’25 (17) (24) (13) (29) (83)
’24 (15) (10) (2) (17) (44)
’23 (14) (16) (12) (10) (52)
’22 (12) (7) (16) (14) (49)
’21 5 (6) (6) (12) (18)
’20 (1) (2) (1) (2) (4)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.39) (0.35) — — —
’25 (0.38) (0.55) (0.39) (0.51) (1.83)
’24 (0.30) (0.11) (0.51) (0.36) (1.28)
’23 (0.42) (0.42) (0.25) (0.25) (1.32)
’22 (0.32) (0.41) (0.40) (0.39) (1.52)
’21 (2.06) (0.62) (0.26) (0.33) (1.39)
’20 (0.03) (2.76) (1.33) — (7.41)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 14.39 9.39 5.65 7.79 13.62

Analyst estimates 2026–2028

Powerpack
High — — — — — 37.99 20.85 23.64 71.71 61.59
People
People Employees — — — — 16 33 60 64 81 109
Revenue/emp, $m — — — — 0.00 0.11 0.14 0.13 0.13 0.09
Income, $m
Income, $m Revenue — — — — — 4 9 8 11 10
Gross margin, % — — — 0.00 0.00 100.00 100.00 100.00 100.00 100.00
EBT — — — (4) (7) (33) (63) (58) (69) (114)
EBT margin, % — — — 0.00 0.00 (898.32) (732.22) (721.18) (651.62) (1,136.25)
Net income — 0 — (4) (7) (33) (63) (58) (69) (114)
Depreciation — — — 0 0 0 (1) (6) (9) (16)
Per share, $
Per share, $ Revenue — — — 0.00 0.00 0.15 0.21 0.18 0.20 0.16
Earnings — — — (5.98) (7.41) (1.39) (1.52) (1.32) (1.28) (1.83)
Cash flow — — — (5.72) (4.77) (0.72) (1.03) (1.15) (0.82) (1.33)
Capex — — — 0.00 0.00 (0.06) (0.16) (0.04) (0.01) (0.02)
Free cash flow — — — (5.72) (4.77) (0.78) (1.19) (1.19) (0.82) (1.34)
Book value — — — (5.90) 7.63 15.57 7.73 7.82 19.03 15.44
Shares, m — — — 1 1 24 41 44 54 62
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.00 0.00
P/S — — — — — 127.65 67.51 60.01 271.80 44.23
P/B — — — — — 1.27 1.81 1.41 2.81 0.89
EV/Sales — — — — — 24.55 29.54 17.45 174.98 (5.76)
EV/FCF — — — — — (4.84) (5.15) (2.69) (41.94) 1.34
Cash, $m
Cash, $m Operating cash flow — — — (4) (4) (17) (43) (51) (44) (82)
Capex — — — — — (1) (6) (2) 0 (1)
Free cash flow — — — (4) (4) (18) (49) (52) (44) (83)
Balance, $m
Balance, $m Working capital — — — (4) 13 364 316 336 1,016 951
Total debt — — — 8 22 0 25 — — —
Net debt — — — (1) (8) (375) (327) (344) (1,025) (967)
Shareholders’ equity — — — (4) 7 366 321 344 1,023 957
Returns, %
Returns, % ROA — — — (1,179.38) (80.30) (16.50) (16.96) (15.66) (9.57) (11.02)
ROIC — — — 0.00 0.00 0.00 0.00 (14,209.31) 0.00 0.00
ROE — — — 35.46 60.08 (18.58) (18.36) (17.53) (10.09) (11.48)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Janux Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BCAX Bicara Therapeutics Inc. $1.2B — (loss-making) — — n/m −72.95% (below 0%: shrinking) — 0.00% Compare
DMRA Galecto, Inc. $1.2B — (loss-making) — — n/m −877.51% (below 0%: shrinking) 0.00% 0.00% Compare
VOR Vor Biopharma Inc. $1.1B — (loss-making) — — n/m −47.59% (below 0%: shrinking) 0.00% — Compare
NBTX Nanobiotix S.A. - Sponsored ADR $1.1B — (loss-making) — −71.69% (below 0%: shrinking) n/m −177.26% (below 0%: shrinking) 0.00% 0.00% Compare
REPL Replimune Group, Inc. $1.1B — (loss-making) — — n/m +5.04% (above 0%: growing) 0.00% 0.00% Compare
IMTX Immatics N.V. $1.1B — (loss-making) — (loss-making) +97.71% (above 0%: growing) n/m −44.41% (below 0%: shrinking) 100.00% (734.95%) Compare
JANX Janux Therapeutics, Inc. $1.1B — (loss-making) — (loss-making) +2,238.72% (above 0%: growing) n/m +150.57% (above 0%: growing) 100.00% (308.66%)
MNKD MannKind Corporation $1.0B — (loss-making) — (loss-making) +42.92% (above 0%: growing) n/m −399.41% (below 0%: shrinking) 72.99% (0.32%) Compare
SVRA Savara Inc. $973.9M — (loss-making) — (loss-making) — n/m −14.05% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $1.1B — — +42.92% — −60.27% 0.00% 0.00%

All 614 Biotechnology stocks →

Janux Therapeutics, Inc. (JANX) key facts

  • Concern: Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
  • Concern: Janux Therapeutics, Inc. reported a net loss of $113.6 million, or a loss of $1.83 per share, for fiscal 2025.
  • Janux Therapeutics, Inc. (JANX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, JANX traded at $16.49, a market capitalization of $1.1 billion.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 43.2× sales.
  • Return on equity was −11.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 11.61 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Janux Therapeutics, Inc. (JANX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/JANX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com